Terminate the lice cycle.

Natroba™ (spinosad) is a proven safe and effective solution for today’s head lice issues and infestations.1

Provides superior efficacy

Natroba™ is the only FDA-approved prescription head lice treatment that demonstrated superior efficacy to Nix® (permethrin 1%) in two head-to-head clinical trials.1

Wheat grass
Soil
Mother & child

Limits disruption to active households

Natroba™ only requires a 10-minute application—with no nit combing.2

Clock with ten minutes
Father & son

Nix® is a registered trademark of Prestige Brands, Inc.

 

References:

  1. Stough D, Shellabarger S, Quiring J, Gabrielsen A. Efficacy and safety of spinosad and permethrin crème rinses for pediculosis capitis (head lice). Pediatrics. 2009;124(3): e389-395.
  2. Natroba prescribing information.
  3. IQVIA 2016-2018.
  4. Data on File.

NAT-RRW7-000

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.